

Table 1: Cure rates* in studies for female and male patients with UUI

Follow-up:	3m	6m	12m	18m	2y	3y	5y
Treatment - WOMEN							
Antimuscarinic		21%					
- Darifenacin**	38%	41%	42%		43.8%		
- Fesoterodine	63%; 62%; 64%; 49.2%; 57.8%						
- Oxybutynine	25.2%; 20%;						
- Solifenacin	58%; 59%; 56.2%; 59.6%	11%	58%				
- Tolterodine	13%; 56%; 57.2%; 49%	70%	45.1%				
- Tolterodine + BI		NR					
- Trosipium	35.6%; 20.5%						
Adrenergic drugs (Mirabegron)	47.1%		43.4%; 45.8%				
Neuromodulation		39%					15% (10y: 17%)
Neuromodulation+PFMR	93%						
TVT		92%					
Botulinum toxin	35%; 22.9%; 15.9% - 50.9%	31.3%					
Treatment - MEN							
Solifenacin+Tamsulosin	NR						
PFMT-Supervised			24%; 35%				
Lifestyle Advice - Unsupervised			23%; 38%				

*) Cure defined as 'cure', 'objective cure', 'success (dry)' or Complete continence, **) reductions of $\geq 90\%$ from feeder-study baseline in incontinence episodes/week
 BI= Behavioral interventions; TVT= Tension-free vaginal tape